Literature DB >> 3263777

Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy.

M S Jochelson1, T S Herman, P C Stomper, P M Mauch, W D Kaplan.   

Abstract

Detection of all sites of lymphoma is imperative for accurate planning of radiation therapy. In patients with Hodgkin disease, mantle radiation is used to treat the thoracic lymph nodes; in those with early-stage or nonbulky disease, mantle and paraaortic radiation may be the only treatment given. CT scanning of the chest adds important information to that obtained from chest radiographs. Gallium-67 scintigraphy has also been used to provide additional information on sites of active tumor. To determine the usefulness of 67Ga-citrate scintigraphy in planning the portals for radiation therapy, we analyzed the radiation treatment plans in 26 consecutive patients with Hodgkin disease; in all 26 patients, the disease had been staged by chest radiographs, chest CT scans, and gallium-67 images. Gallium-67 imaging alone provided unique information that affected the treatment plans in three patients (12%). The combined results of gallium-67 imaging and CT scans influenced the planning of radiation therapy in eight patients (31%). Gallium-67 imaging was found to be an important adjunctive study for optimal planning of radiation therapy in patients with Hodgkin disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263777     DOI: 10.2214/ajr.151.6.1229

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  2 in total

Review 1.  Current role of gallium scanning in the management of lymphoma.

Authors:  A F McLaughlin; M A Magee; R Greenough; K C Allman; A E Southee; S R Meikle; B F Hutton; D E Joshua; G J Bautovich; J G Morris
Journal:  Eur J Nucl Med       Date:  1990

Review 2.  Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.

Authors:  Einat Even-Sapir; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-18       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.